Eylea is approved in Japan for treatment of Myopic Choroidal Neovascularization (myopic CNV).- Bayer Healthcare
Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Eylea (aflibercept solution for injection) for the treatment of Myopic Choroidal Neovascularization (myopic CNV). In Japan, pathologic myopia and the associated myopic CNV is the second most common cause of blindness.
The approval is based on positive data from the Phase III MYRROR study in Myopic CNV. The topline results, where patients receiving Eylea had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of 12.1 letters, compared to a loss of 2 letters in patients receiving sham injections ( p<0.0001), were announced at the american academy of ophthalmology congress in new orleans.>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.